| Name | Title | Contact Details |
|---|
axialHealthcare offers an evidence-driven, predictive solution that limits opioid misuse and optimizes care for patients with pain or opioid use disorder.
NextGate`s mission is to address the fundamental challenge of data management in the healthcare industry: the uncertainties and missed opportunities caused by duplicate and disconnected records in a data population. While implementing interface engine technology for hospitals in the early 1990s, we noticed a troubling trend – as application systems became integrated and exchanged data with each other, problems caused by duplicate and incomplete patient records (previously confined to one system and its MPI) multiplied and contaminated the data quality of other systems. Because this technical issue could impact a patient`s health, we made it our goal to find a solution. The result was MatchMetrix®, a technology platform that invokes probabilistic and other algorithms to identify duplicate and potentially duplicate records within a single data set or across multiple data sets. All records are assigned a unique ID that serves as an enterprise-wide universal key for accurate identification and efficient data exchange. Duplicate records are merged, related records are linked together, and all of them are indexed into a trusted, consistent, and reliable registry accessible to any authorized application or user. We continue to develop solutions that help manage information that facilitates care team collaboration with accuracy and reliability.
The US Oncology Network is one of the nation’s largest networks of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. A physician-led organization, The US Oncology Network unites like-minded physicians and clinicians around a common vision of improving patient outcomes and quality of life. Leveraging healthcare information technology, shared best practices, evidence-based guidelines and quality measurements, physicians within The US Oncology Network are pioneering new ways to achieve this vision. The US Oncology Network is committed to strengthening patient access to integrated care in local communities across the nation, including collaboration with a variety of payers, hospitals and academic institutions. The US Oncology Network is supported by McKesson Specialty Health, a division of McKesson Corporation focused on empowering a vibrant and sustainable community patient care delivery system.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Cianna Medical Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Aliso Viejo, CA. To find more information about Cianna Medical Inc, please visit www.ciannamedical.com